This presentation and any accompanying oral commentary have been prepared by Turnstone Biologics Corp. ("Turnstone") for informational purposes only and not for any other purpose. All statements contained in this present

Corporate Presentation March 2024

Nasdaq: TSBX Non-Confidential Exhibit 99.1

This presentation and any accompanying

oral commentary have been prepared by Turnstone Biologics Corp. ("Turnstone") for informational purposes only and not for any other purpose. All statements contained in this presentation and the accompanying oral commentary, other than

statements of historical facts, are forward-looking statements, including: statements about our expectations regarding the potential benefits, activity, effectiveness, and safety of our Selected tumor-infiltrating lymphocyte (TIL) product candidates

and programs; our expectations with regard to the design and results of our research and development programs, preclinical studies, and clinical trials, including the timing and availability of data from such trials; our preclinical, clinical, and

regulatory development plans for our Selected TIL product candidates and programs, including the timing or likelihood of regulatory filings and approvals for our Selected TIL product candidates; our ability to maintain existing, and establish new,

strategic collaborations, licensing, or other arrangements; our ability to improve process to improve manufacturing processes; and our business strategy. These statements involve substantial known and unknown risks, uncertainties and other factors

that may cause our actual results, timing of results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks and uncertainties include

those factors discussed in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on November 13, 2023, under the heading "Risk Factors," and other documents Turntone has filed, or will file,

with the SEC. These filings, when available, are available on the investor relations section of our website at ir.turnstonebio.com and on the SEC's website at www.sec.gov. New risks emerge from time to time. It is not possible for our

management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those anticipated or implied

in the forward-looking statements. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events

could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that

subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by

applicable law. Except as required by law, none of Turnstone, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes any representation or warranty as to

the accuracy or completeness of any information contained in this presentation and shall have no liability for any representations (expressed or implied) contained in, or for any omissions from, this presentation. This presentation contains

trademarks, service marks, trade names and copyrights of Turnstone and other companies which are the property of their respective owners. This presentation discusses product candidates that are under clinical study and which have not yet been

approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. This presentation also contains estimates and

other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such

estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Disclaimers

Turnstone is Pioneering Advancements

in Selected TIL Therapy Next-Generation Therapy Designed to Treat and Cure Solid Tumors OUR MISSION Profoundly transform the treatment paradigm for patients with a broad range of solid tumors with next-generation TIL therapies that overcome the

limitations of current treatment options Mike Mielnik Senior Scientist, Turnstone Biologics

Solid Tumors Represent a Serious Unmet

Medical Need Approximately 90% of all new cancers per year are solid tumors 1National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER), accessed March 2024; 2Cancer Metastasis: Guan X. Cancer Metastases: Challenges and

Opportunities. Acta Pharm Sin B. 2015 Sep;5(5):402-18.; 3Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May

3;2(5):e192535.; 4United Stated Food and Drug Association (US FDA) approval granted on 02/16/2024; News release Checkpoint inhibitors only benefit a fraction of cancer patients3 Targeted and other cell therapies have shown only limited success One

FDA approved TIL therapy and only in advanced melanoma4 1.6M 500K 90%+ new cancer patients1 deaths with low long-term survival1 mortality in metastatic disease2 In the U.S. Each Year New Therapeutic Options Urgently Needed

Indication Spotlight: Colorectal

Cancer (CRC) 2nd Leading Cause of U.S. Cancer Deaths1 3rd 153K 53K most commonly diagnosed cancer2 expected new cases this year3 number of deaths expected in 20244 Difficult-To-Treat Tumor Unresponsive To Most Immune-Based Therapies Immunologically

"cold" tumor characterized by low tumor mutational burden (TMB) Turnstone is Tackling Solid Tumors of Greatest Need Our focus is on colorectal cancer, head and neck cancer, uveal melanoma and breast cancer We believe the key to

overcoming challenges of CRC and other "cold" tumors is large numbers of on-target tumor-reactive T cells which is the foundation for Turnstone's approach of Selected TIL therapy 2CA: A Cancer Journal for Clinicians -

Colorectal Cancer Statistics, 2023 - DOI: 10.3322/caac.21772; 3, 4National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER), accessed March 2024 1American Cancer Society. Cancer Facts & Figures 2024;

Turnstone is Pioneering Advancements

in Selected TIL Therapy Next-generation therapy designed to treat and cure solid tumors Differentiated approach centered around tumor-reactive T cell selection (Selected TILs) Lead asset, TIDAL-01, being evaluated in multiple Phase 1 studies with

initial clinical data expected in mid-2024 Targeting underserved solid tumor patient populations, including CRC, HNSCC, uveal melanoma and breast cancer TILs have been recently approved by the FDA* for the treatment of cutaneous melanoma FDA =

United States Food and Drug Administration; CRC = Colorectal cancer; HNSCC = Head and neck squamous cell carcinoma *Approval for Amtagvi granted on 02/16/2024; US FDA news release

Sammy Farah, MBA, PhD Chief Executive

Officer Vijay Chiruvolu, MBA, PhD Interim Chief Technology Officer Venkat Ramanan, PhD Chief Financial Officer Stewart Abbot, PhD Chief Scientific Officer Saryah Azmat Chief Business Officer Mike Burgess, MBChB, PhD Interim Chief Medical Officer 20+

years of scientific, business and executive management experience in biotech industry Held senior positions at Merck, Immune Design, and Synthetic Genomics Previously at Versant Ventures specializing in biotechnology investing and new company

formation 10+ years of experience in biopharma business development, corporate strategy and capital formation Former Global Lead for Oncology Search & Evaluation at Bristol-Myers Squibb, executing over 15 major transactions from preclinical to

clinical development 27+ years of manufacturing and process development experience Served as SVP of Global Process Development-Cell Therapy at Kite Pharma/Gilead Sciences, responsible for the CMC/process development leading to regulatory approval of

two cell therapy products, Yescarta and Tecartus 20+ years of biopharma finance and operations experience Joined from Seagen where he led the Finance function as the company launched several products, expanded global footprint and executed multiple

strategic transactions 20+ years experience building and leading clinical development Led strategy and execution of translational medicine across all therapeutic areas as SVP of Cardiovascular, Fibrosis and Immunoscience Development at Bristol-Myers

Squibb Previous Global Head of Oncology Research and Early Development at Roche 20+ years of R&D experience in cell-based and immuno-oncology products Former CSO and COO at Adicet Bio, responsible for R&D activities for allogeneic gamma

delta T cell therapies Previously CDO at Fate Therapeutics, developing cellular immunotherapies Turnstone Executive Team Proven experience across all areas and stages of drug development

Distinguished Advisors Key

Collaborators Simon Turcotte, MD, MSc Associate Professor of Surgery; Lead of Adoptive T Cell Cancer Immunotherapy Program, University of Montreal Hospital Research Centre (CRCHUM) James Mul , PhD Associate Center Director of Translational

Science Moffitt Cancer Center Steven A. Rosenberg, MD, PhD Chief of Surgery Branch National Cancer Institute Malcolm Brenner, MD, PhD Professor, Center for Cell and Gene Therapy Baylor College of Medicine Thomas Dubensky Jr., PhD Founder and Advisor

Tempest Therapeutics Bernard Fox, PhD Chief, Laboratory of Molecular and Tumor Immunology Providence Cancer Institute Adrian Hill, PhD Director, The Jenner Institute University of Oxford Robert Seder, MD Chief, Cellular Immunology Section Vaccine

Research Center National Institutes of Health Alan Melcher, PhD Team Leader Translational Immunology The Institute of Cancer Research Nicholas Restifo, MD Special Volunteer National Institutes of Health Eric Tran, PhD ACT Laboratory Lead Providence

Cancer Institute Jeffrey S. Weber, MD, PhD Deputy Director, PCC; Co-Director, Melanoma Research Program NYU-Langone Cancer Center Turnstone External Network Supported by prominent scientific and corporate advisors and collaborators Tassos

Gianakakos, MBA Former CEO MyoKardia

Turnstone Pipeline Opportunity to

address broad set of solid tumor patient populations Product Overview Program Key Indications Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone Selected TILs TIDAL-01 TIDAL-02 Initial clinical data in mid-2024 IND submission IND

submission Tumor-reactive Selected TILs Combination with viral immunotherapy Selected TILs with next-gen manufacturing and TIL quality enhancements Solid tumors Solid tumors Colorectal cancer, Head and neck cancer, Cutaneous and non-cutaneous

melanomas Breast cancer, Colorectal cancer, Head and neck cancer, Uveal melanoma Investigator sponsored trials at Moffitt Cancer Center Moffitt Collaboration

SELECTED TILs AND TIDAL-01

Corporate Presentation | March 2024

Expanding the Frontiers of TIL

Therapy Building upon first-to-market TIL therapy to deliver differentiated product with unique market opportunity Turnstone is developing the Next-Generation of TIL Therapies First approval for a TIL therapy brings new option for solid tumors

Amtagvi is the first and only FDA-approved TIL therapy, and the only T cell therapy for a solid tumor Amtagvi is a first-generation bulk TIL therapy approved to treat only advanced melanoma* Increasing total number of tumor-reactive T cells is key

area of differentiation Academic studies provide early clinical evidence for selected TIL approach Potential to broaden efficacy into additional solid tumors with critical unmet need Bulk TILs have failed to show success in most solid tumors outside

melanoma Significant opportunity for next-gen products More targeted and potent tumor killing is a must *Approval for Amtagvi granted on 02/16/2024; US FDA news release

Next-generation TIL therapy based

on isolation, selection and expansion of tumor-reactive T cells to improve product potency Designed to address a broad range of solid tumor types Selected TILs Selected TILs Have Potential for More Targeted Tumor Killing Starting materials for

solid tumors typically have small number and proportion of tumor-reactive T cells Solid Tumors Tumor-reactive T cells can contribute to tumor killing Bulk TILs: Non-specific expansion of all cells Selected TILs: Specific expansion of tumor-reactive

T cells 109+ cells with low number and proportion (reported median < 3%) of on target tumor-reactive T cells Large number and proportion of suppressive bystander cells Inefficient tumor killing observed to date 109+ cells with large number and

proportion (targeting > 70%) of on-target tumor-reactive T cells Low number and proportion of suppressive bystander cells Potential for targeted tumor killing Tumor-Reactive T Cells Suppressive Bystander Cells 1 We define potency as the specific

ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in the manner intended, to effect a given result

Early academics working on

first-generation TILs led to development of a leading Bulk TIL company's current process Success to date has been limited to melanoma Bulk TILs Melanoma Sheba, NCI, Moffitt, MD Anderson Melanoma Bulk TIL leading competitor clinical development

initiation Cervical NCI Melanoma and Cervical Competitor Data Release Head and Neck Cancer Competitor Data Release Melanoma Competitor Data Release Selected TILs Bile Duct Tran et. al (NCI) Colorectal Cancer Tran et. al (NCI) Breast Cancer,

Colorectal Cancer, Head and Neck Cancer, Uveal Melanoma** Breast Zacharakis et al (NCI) Lung Creelan et. al (Moffitt) Selected TILs Are Based on Advances from Academia Melanoma Rosenberg et. al, NCI Melanoma First FDA approval for TIL therapy

(Amtagvi)* *Approval for Amtagvi granted on 02/16/2024; US FDA news release; **Indications being evaluated in ongoing Phase 1 studies Recent academic data in next-generation TILs has provided early clinical evidence for next-generation selected TIL

approach Objective responses extended to other major solid tumor types

*7 patients received TIL product

with confirmed tumor-specific reactivity out of 13 patients who were evaluable for clinical response 6 patients enrolled on adoptive cell transfer protocol of enriched neoantigen-specific TIL out of 28 patients who contained TIL that

recognized at least one immunogenic somatic mutation 1 Early academic selection and enrichment strategies typically utilized fragment-based selection and expansion approaches. Following harvest and dissection of the tumor, small numbers of tumor

fragments were placed into separate multi-well tissue culture dishes and cultured with the tumor or manufactured antigens. TIL populations that were activated by exposure to tumor antigens in culture would then be identified based on cytokine

expression and/or T cell activation marker expression, and only those activated TIL populations would be expanded for use in the final product Tumor Type N Response Source Academic Selected TILs Bile Duct (Cholangiocarcinoma) 1 1 PR NCI - Tran et

al; Science 2014 Colorectal Cancer 1 1 PR NCI - Tran et al; NEJM 2016 Non-Small Cell Lung Cancer 7* 2 CRs, 1PR Moffitt - Creelan et al; Nature Medicine 2021 Breast Cancer 6 1 CR, 2 PRs NCI - Zacharakis et al; JCO 2022 Early academic selection

strategies1 deployed at the NCI have demonstrated clinical POC Historical data from the NCI demonstrates limited evidence of benefit of Bulk TILs in epithelial malignancies Tumor Type N Response Source Bulk TILs Various Solid Tumors (including

Colorectal, Bile Duct, Pancreas, Breast, Gastric) 50+ No success NCI - Rosenberg AACR 2020 / NCT01585428 Clinical Validation of Selected TILs

Tumor sequencing to identify all

possible tumor mutations (antigens) Synthesize the tumor mutations in the form of long peptides Pulse patient-derived dendritic cells with the synthesized tumor antigens for natural processing and presentation Incubate TILs with presented tumor

antigens and select tumor-reactive T cells based on activation markers TIDAL-01 Process Designed to select a more potent population of T cells The TIDAL-01 process is similar to standard bulk TIL processes but includes a selection step designed to

create a TIL product with a significantly higher proportion of tumor-reactive T cells for more effective tumor killing Standard TIL Process TIDAL-01 Selected TILs Tumor Harvest TIL Isolation TIL Expansion Bulk TILs Product Infusion Tumor Harvest TIL

Isolation TIL Expansion Selected TILs Product Infusion Key Selection Steps TIL SELECTION

TIDAL-01 product consists of

diverse set of T cells with confirmed tumor-reactivity (TCRs) Selected tumor-reactive T cells are typically found in only very low frequencies in Bulk TILs These TCRs within Selected TILs deliver higher frequency of immunostimulatory cytokine

expression in CD4+ and CD8+ T cells vs. Bulk TILs CD4+ T cells CD8+ T cells TIDAL-01 Designed to Select for Tumor-Reactive T Cells that are Typically Only Found in Very Low Levels in Bulk TILs TIDAL-01 Selected TILs TIDAL-01 Selected TILs TCR

Analyses IFNg Expression Analyses Selection of tumor-reactive TIL enriches TCR repertoire 31% of TIDAL-01 selected CD8+ T cells reacted to peptides compared to 3% in Bulk TIL, representing approx. a 10-fold increase 26% of TIDAL-01 selected CD4+ T

cells reacted to peptides compared to 10% in Bulk TIL, representing approx. a 2.6-fold increase The top 12 enriched TCRs represent 60% of the TIDAL-01 final product while these same TCRs represent less than 2% of the bulk TILs and bystander cells

Colorectal Cancer Patient Sample % TCR Frequency % of Final Product % IFNg + of CD8+ Cells % IFNg + of CD4+ Cells Bulk TILs Bystander Cells Bulk TILs Bystander Cells TIL + Unloaded APC TIL + Peptide Loaded APC TIL + Unloaded APC TIL + Peptide Loaded

APC TIDAL-01 Selected TILs Bulk TILs Bystander Cells **** = p < 0.0001

TIDAL-01 Displays Higher Capacity

to Kill Tumor Cells Melanoma Patient Sample Time: 0 Time: 2 Days TIDAL-01 Selected TILs Bystander Cells Tumor Only Effector to target ratio: 1:2 Tumor Cells T Cells Dead Cells (CAS3/7)

TIDAL-01 CLINICAL DEVELOPMENT